FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387579413> ?p ?o ?g. }

• W4387579413 endingPage "450" @default.
• W4387579413 startingPage "450" @default.
• W4387579413 abstract "<ns5:p><ns5:bold>Background: </ns5:bold>Falciparum malaria remains a global health problem. Two vaccines, based on the circumsporozoite antigen, are available. RTS, S/AS01 was recommended for use in 2021 following the advice of the World Health Organisation (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization and WHO Malaria Policy Advisory Group (MPAG). It has since been pre-qualified in 2022 by the WHO. R21 is similar to RTS, S/AS01, and recently licensed in Nigeria, Ghana and Burkina Faso following Phase 3 trial results.</ns5:p><ns5:p> <ns5:bold>Methods: </ns5:bold>We conducted a Phase 1b age de-escalation, dose escalation bridging study after a change in the manufacturing process for R21. We recruited healthy adults and children and used a three dose primary vaccination series with a booster dose at 1–2 years. Variable doses of R21 and adjuvant (Matrix-M ™) were administered at 10µgR21/50 µg Matrix-M™, 5µgR21/25µg Matrix-M™ and 5µgR21/50µg Matrix-M™ to 20 adults, 20 children, and 51 infants.</ns5:p><ns5:p> <ns5:bold>Results: </ns5:bold>Self-limiting adverse events were reported relating to the injection site and mild systemic symptoms. Two serious adverse events were reported, neither linked to vaccination. High levels of IgG antibodies to the circumsporozoite antigen were induced, and geometric mean titres in infants, the target group, were 1.1 (0.9 to 1.3) EU/mL at day 0, 10175 (7724 to 13404) EU/mL at day 84 and (following a booster dose at day 421) 6792 (5310 to 8687) EU/mL at day 456.</ns5:p><ns5:p> <ns5:bold>Conclusions: </ns5:bold>R21/Matrix-M™ is safe, and immunogenic when given at varied doses with the peak immune response seen in infants 28 days after a three dose primary vaccination series given four weeks apart. Antibody responses were restored 28 days after a 4<ns5:sup>th</ns5:sup> dose given one year post a three dose primary series in the young children and infants.</ns5:p><ns5:p> <ns5:bold>Registration: </ns5:bold>Clinicaltrials.gov (NCT03580824; 9<ns5:sup>th</ns5:sup> of July 2018; Pan African Clinical Trials Registry (PACTR202105682956280; 17<ns5:sup>th</ns5:sup> May 2021).</ns5:p>" @default.
• W4387579413 created "2023-10-13" @default.
• W4387579413 creator A5008569059 @default.
• W4387579413 creator A5009075899 @default.
• W4387579413 creator A5011091618 @default.
• W4387579413 creator A5012895894 @default.
• W4387579413 creator A5027355283 @default.
• W4387579413 creator A5033735799 @default.
• W4387579413 creator A5033873978 @default.
• W4387579413 creator A5038203672 @default.
• W4387579413 creator A5039352548 @default.
• W4387579413 creator A5040569205 @default.
• W4387579413 creator A5040714500 @default.
• W4387579413 creator A5044551272 @default.
• W4387579413 creator A5044978874 @default.
• W4387579413 creator A5053421628 @default.
• W4387579413 creator A5054098347 @default.
• W4387579413 creator A5056427206 @default.
• W4387579413 creator A5057127804 @default.
• W4387579413 creator A5059693320 @default.
• W4387579413 creator A5068570467 @default.
• W4387579413 creator A5071540899 @default.
• W4387579413 creator A5075584371 @default.
• W4387579413 creator A5080540974 @default.
• W4387579413 creator A5093051818 @default.
• W4387579413 creator A5093051819 @default.
• W4387579413 date "2023-10-12" @default.
• W4387579413 modified "2023-10-14" @default.
• W4387579413 title "Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya" @default.
• W4387579413 cites W2101661555 @default.
• W4387579413 cites W2117559066 @default.
• W4387579413 cites W2145219708 @default.
• W4387579413 cites W2582269309 @default.
• W4387579413 cites W2605491919 @default.
• W4387579413 cites W2893049758 @default.
• W4387579413 cites W2983844272 @default.
• W4387579413 cites W3158165973 @default.
• W4387579413 cites W4295633071 @default.
• W4387579413 cites W4307412994 @default.
• W4387579413 doi "https://doi.org/10.12688/wellcomeopenres.19795.1" @default.
• W4387579413 hasPublicationYear "2023" @default.
• W4387579413 type Work @default.
• W4387579413 citedByCount "0" @default.
• W4387579413 crossrefType "journal-article" @default.
• W4387579413 hasAuthorship W4387579413A5008569059 @default.
• W4387579413 hasAuthorship W4387579413A5009075899 @default.
• W4387579413 hasAuthorship W4387579413A5011091618 @default.
• W4387579413 hasAuthorship W4387579413A5012895894 @default.
• W4387579413 hasAuthorship W4387579413A5027355283 @default.
• W4387579413 hasAuthorship W4387579413A5033735799 @default.
• W4387579413 hasAuthorship W4387579413A5033873978 @default.
• W4387579413 hasAuthorship W4387579413A5038203672 @default.
• W4387579413 hasAuthorship W4387579413A5039352548 @default.
• W4387579413 hasAuthorship W4387579413A5040569205 @default.
• W4387579413 hasAuthorship W4387579413A5040714500 @default.
• W4387579413 hasAuthorship W4387579413A5044551272 @default.
• W4387579413 hasAuthorship W4387579413A5044978874 @default.
• W4387579413 hasAuthorship W4387579413A5053421628 @default.
• W4387579413 hasAuthorship W4387579413A5054098347 @default.
• W4387579413 hasAuthorship W4387579413A5056427206 @default.
• W4387579413 hasAuthorship W4387579413A5057127804 @default.
• W4387579413 hasAuthorship W4387579413A5059693320 @default.
• W4387579413 hasAuthorship W4387579413A5068570467 @default.
• W4387579413 hasAuthorship W4387579413A5071540899 @default.
• W4387579413 hasAuthorship W4387579413A5075584371 @default.
• W4387579413 hasAuthorship W4387579413A5080540974 @default.
• W4387579413 hasAuthorship W4387579413A5093051818 @default.
• W4387579413 hasAuthorship W4387579413A5093051819 @default.
• W4387579413 hasBestOaLocation W43875794131 @default.
• W4387579413 hasConcept C126322002 @default.
• W4387579413 hasConcept C147483822 @default.
• W4387579413 hasConcept C187212893 @default.
• W4387579413 hasConcept C197934379 @default.
• W4387579413 hasConcept C203014093 @default.
• W4387579413 hasConcept C22070199 @default.
• W4387579413 hasConcept C2778048844 @default.
• W4387579413 hasConcept C2778371730 @default.
• W4387579413 hasConcept C2780801004 @default.
• W4387579413 hasConcept C2780868878 @default.
• W4387579413 hasConcept C2781034427 @default.
• W4387579413 hasConcept C2781074509 @default.
• W4387579413 hasConcept C71924100 @default.
• W4387579413 hasConceptScore W4387579413C126322002 @default.
• W4387579413 hasConceptScore W4387579413C147483822 @default.
• W4387579413 hasConceptScore W4387579413C187212893 @default.
• W4387579413 hasConceptScore W4387579413C197934379 @default.
• W4387579413 hasConceptScore W4387579413C203014093 @default.
• W4387579413 hasConceptScore W4387579413C22070199 @default.
• W4387579413 hasConceptScore W4387579413C2778048844 @default.
• W4387579413 hasConceptScore W4387579413C2778371730 @default.
• W4387579413 hasConceptScore W4387579413C2780801004 @default.
• W4387579413 hasConceptScore W4387579413C2780868878 @default.
• W4387579413 hasConceptScore W4387579413C2781034427 @default.
• W4387579413 hasConceptScore W4387579413C2781074509 @default.
• W4387579413 hasConceptScore W4387579413C71924100 @default.
• W4387579413 hasFunder F4320307874 @default.
• W4387579413 hasFunder F4320332999 @default.
• W4387579413 hasLocation W43875794131 @default.

• next